Study of Erlotinib and Metformin in Triple Negative Breast Cancer

NCT01650506 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Metformin
DRUG: Erlotinib

Sponsor

Columbia University

Collaborators

[object Object]
[object Object]